{"id":7757,"date":"2026-05-07T17:22:09","date_gmt":"2026-05-07T17:22:09","guid":{"rendered":"https:\/\/www.europesays.com\/korea\/7757\/"},"modified":"2026-05-07T17:22:09","modified_gmt":"2026-05-07T17:22:09","slug":"sk-pharmteco-collaborates-with-axle-informatics-and-the-national-institutes-of-health-to-advance-rare-disease-gene-therapy-programs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/korea\/7757\/","title":{"rendered":"SK pharmteco Collaborates with Axle Informatics and the National Institutes of Health to Advance Rare Disease Gene Therapy Programs"},"content":{"rendered":"

RANCHO CORDOVA, Calif., May 07, 2026 (GLOBE NEWSWIRE)<\/a> — SK pharmteco<\/a> today announced a strategic partnership with Axle Informatics<\/a> and the National<\/a> Institutes of Health (NIH) to advance the development of gene therapies for rare diseases. This partnership, focused on viral vector programs, underscores SK pharmteco\u2019s commitment to the rare disease sector and its role as a key technical partner for leading research institutions.<\/p>\n

As a subcontractor to the NIH, SK pharmteco is working with Axle Informatics, the NIH\u2019s primary contractor, to support efforts to accelerate the translation of academic research into clinical practice. The collaboration pairs SK pharmteco\u2019s advanced manufacturing capabilities with leading principal investigators (PIs) at the NIH to address significant unmet medical needs.<\/p>\n

“Collaborating with the NIH and Axle Informatics marks an important step in our efforts to support patients with rare diseases,\u201d said John Lee, Global Head of Viral Vector at SK pharmteco. “Rare disease programs often operate under significant development and funding constraints, making reliable technical execution and flexible partnerships especially important. By working closely with Axle Informatics and NIH investigators, we are applying our lentiviral manufacturing and analytical expertise to help advance these programs toward the clinic for patients with serious unmet needs.\u201d<\/p>\n

The inaugural program under this partnership focuses on producing lentiviral vectors (LVV) to treat rare inherited blood and metabolic disorders. SK pharmteco has worked closely with NIH investigators to advance this effort. As part of that work, SK pharmteco manufactured drug substance intended for future ex vivo transduction of patients\u2019 CD34+ hematopoietic stem cells and managed batch-release testing, with most analytical assays performed in-house at its specialized laboratories.<\/p>\n

“This effort illustrates how integrated partnerships can accelerate the advancement of translational research into clinical outcomes,\u201d said Gary Mays, Chief Operating Officer at Axle Informatics. “Axle is focused on connecting capabilities across the NIH environment, and our collaboration with SK pharmteco adds essential manufacturing strength to help NIH advance promising gene therapies for patients in need.\u201d<\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

This partnership highlights SK pharmteco\u2019s ability to serve as a strong technical partner for both emerging biotech firms and large-scale public institutions. It also reflects SK pharmteco\u2019s broader efforts to support rare disease innovators through partnership models designed to help advance complex programs into the clinic. By providing specialized viral vector development, manufacturing, and analytical support, SK pharmteco continues to position itself as a partner for academic investigators, public institutions, non-profits, and emerging biotech companies working to translate promising therapies into the clinic.\u00a0<\/p>\n

This collaboration was funded in part by the National Institutes of Health.<\/p>\n

About SK pharmteco<\/p>\n

SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company\u2019s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market. Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea\u2019s second-largest conglomerate.<\/p>\n

Contact:<\/p>\n

Keith Bowermaster, APR, CCMP<\/p>\n

Communications Consultant<\/p>\n

[email\u00a0protected]<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"RANCHO CORDOVA, Calif., May 07, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a strategic partnership with Axle…\n","protected":false},"author":2,"featured_media":7758,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[6012,941,6009,6008,6014,6015,2878,6010,6011,1490,4275,3042,3747,6013,241,240,3706,6016,494,4575],"class_list":{"0":"post-7757","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sk","8":"tag-advance","9":"tag-and","10":"tag-axle","11":"tag-collaborates","12":"tag-disease","13":"tag-gene","14":"tag-health","15":"tag-informatics","16":"tag-institutes","17":"tag-national","18":"tag-of","19":"tag-pharmteco","20":"tag-programs","21":"tag-rare","22":"tag-sk","23":"tag-sk-group","24":"tag-the","25":"tag-therapy","26":"tag-to","27":"tag-with"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/7757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/comments?post=7757"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/7757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media\/7758"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media?parent=7757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/categories?post=7757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/tags?post=7757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}